INAXAPLIN: A Promising Treatment for APOL1-mediated Proteinuric Kidney Disease

What is INAXAPLIN?

INAXAPLIN, also known as VX-147, is a new medication being developed to treat APOL1-mediated Proteinuric Kidney Disease (AMKD). It is currently undergoing clinical trials to evaluate its effectiveness and safety.1 INAXAPLIN is taken orally as a film-coated tablet and is being studied in both adults and children with AMKD.

What is APOL1-mediated Proteinuric Kidney Disease (AMKD)?

APOL1-mediated Proteinuric Kidney Disease is a genetic condition that affects the kidneys. It is caused by specific variations in the APOL1 gene, which can lead to kidney damage and loss of kidney function over time. The term "proteinuric" means that people with this condition have high levels of protein in their urine, which is a sign of kidney damage.1

How INAXAPLIN Works

While the exact mechanism of action is not detailed in the provided information, INAXAPLIN is designed to target the underlying cause of AMKD. By addressing the effects of the APOL1 gene variations, it aims to reduce protein in the urine and slow down the progression of kidney disease.1

Clinical Trial Details

The clinical trial for INAXAPLIN is a Phase 2/3 study, which means it is in an advanced stage of testing. Here are some key points about the trial:

• It is a double-blind, placebo-controlled study, which helps ensure reliable results.
• The trial aims to evaluate both the effectiveness and safety of INAXAPLIN.
• It includes both adult and pediatric patients with AMKD.
• The study will last for at least 48 weeks, with some participants being followed for up to 2 years.1

Eligibility Criteria

To participate in the INAXAPLIN trial, patients must meet certain criteria. Some of the key eligibility requirements include:

• Having a specific APOL1 genotype (G1/G1, G2/G2, or G1/G2)
• Being between 12 and 65 years old (18 to 65 for the initial phase)
• Having a certain level of protein in the urine and reduced kidney function
• Not having other underlying causes of kidney disease or diabetes
• Meeting specific health and laboratory criteria1

Potential Benefits

The main goals of the INAXAPLIN treatment are:

1. To reduce the amount of protein in the urine, which is measured as a percentage change in UPCR (Urine Protein to Creatinine Ratio). This is important because high levels of protein in the urine are a sign of kidney damage.
2. To slow down the decline in kidney function, which is measured by the eGFR (estimated Glomerular Filtration Rate) slope. A slower decline in eGFR means the kidneys are losing function more slowly.
3. To decrease the risk of serious kidney-related events, such as:
   • A significant decline in kidney function
   • The need for dialysis or kidney transplant
   • Reaching a very low level of kidney function

These potential benefits could significantly improve the quality of life and long-term health outcomes for people with AMKD.1

Safety Considerations

As with any new medication, safety is a crucial aspect of the INAXAPLIN trial. The researchers are carefully monitoring:

• Any side effects or adverse events reported by participants
• Changes in laboratory test results
• Effects on heart rhythm (through ECG monitoring)
• Changes in vital signs

The trial also excludes people with certain health conditions or risk factors to ensure participant safety. It's important to note that the full safety profile of INAXAPLIN will only be known after the completion of this and potentially other clinical trials.1